Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, acquired neurological disorder with heterogeneous presentation. It is a peripheral nerve system immune-mediated condition which ...

(BPT) – “At first I was kind of like, what is that? What is CIDP? I’ve never heard of that. But then, the relief set in more than confusion … because at least there was a name to what I had.” ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced full results from the pivotal Phase 3 ADVANCE-CIDP 1 clinical trial investigating HYQVIA® [Immune Globulin ...

Vyvgart Hytrulo (efgartigimod alfa/hyaluronidase-qvfc) is a prescription medicine that is used to treat certain muscle and nerve conditions. It is a combination of two medicines, efgartigimod alfa and ...

Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia gravis (MG) and initial results from Period 1 of a mid-stage study of the ...

As many as four percent of the world’s population lives with an autoimmune disease, in which the immune system fails to distinguish between ‘self’ and ‘non-self’ and mistakenly attacks the body, ...

In 2014, Baxter got HyQvia over the FDA finish line for patients with primary immunodeficiency (PI). Eight years and three companies later, Takeda is finding more uses for the subcutaneous treatment.